Responses
Regular and Young Investigator Award Abstracts
Cellular Therapies
301 Preclinical development of AB-2100, a PSMA neovasculature-inducible CA9 CAR resistant to FASL and TGFb mediated suppression for the treatment of ccRCC
Compose a Response to This Article
Other responses
No responses have been published for this article.
